13.2 Ethics, Confidentiality & Generic Substitution

The Four Pillars in Pharmacy Practice

Pharmacy ethics questions on the DHA exam are usually scenario-based applications of the four classical principles:

• Autonomy — respecting the patient's right to informed choice. In practice: explaining options honestly, honouring a competent patient's refusal, and not concealing an error because disclosure is uncomfortable.
• Beneficence — acting for the patient's benefit. In practice: proactively identifying interactions, counselling on adherence, referring red-flag symptoms rather than simply selling a product.
• Non-maleficence — first, do no harm. In practice: refusing to dispense an unsafe or forged prescription even under pressure, checking allergy history, declining to supply antibiotics without a valid prescription.
• Justice — fair treatment and fair allocation. In practice: not prioritising wealthier or pushier customers, applying substitution and pricing rules consistently, and equitable access during shortages.

Exam questions rarely ask for definitions alone; they present a dilemma — for example, a relative demanding information, or a profitable but inappropriate sale — and expect you to pick the option balancing autonomy and confidentiality against genuine harm risk.

Confidentiality and Health-Data Duties

A pharmacist holds health information in confidence as a legal and professional duty, not merely a courtesy. Prescription details, diagnoses inferred from medicines, and even the fact that someone is a patient are protected. Practical rules:

• Family and employer inquiries. Do not disclose a patient's medicines or conditions to spouses, relatives, employers or insurers without the patient's explicit consent — however well-meaning the request. For children and patients lacking capacity, disclosure is to the legal guardian and limited to what care requires.
• Exceptions. Confidentiality may be overridden only in narrow circumstances: to prevent serious harm to the patient or others, or under legal compulsion (a court order or a specific statutory duty to report). Even then, disclose the minimum necessary to the proper authority, and document the decision and its rationale.
• Data handling. Health data must be stored securely, access-restricted, and never posted to social media or discussed in public areas. De-identified teaching use still demands genuine anonymisation.

Informed consent in pharmacy means the patient understands, in language they comprehend, what a medicine is for, how to take it and the material risks before agreeing — consent is a process of communication, not a signature.

Conflicts of Interest, Advertising and Professional Boundaries

Conflicts of interest arise when commercial gain could distort professional judgement — gifts, hospitality or incentive schemes from manufacturers that reward dispensing particular brands. The ethical rule is to avoid, declare and never allow inducements to influence clinical decisions; substitution and recommendation decisions must rest on evidence, regulation and patient need.

Advertising. UAE rules prohibit direct-to-consumer advertising of prescription-only medicines (POM); promotion of POMs is confined to healthcare professionals through regulated channels, while over-the-counter products may be advertised within approved content rules. A pharmacist who promotes a POM brand to the public for a supplier's reward breaches both advertising and conflict-of-interest standards.

Conscientious objection has boundaries: a pharmacist with a genuine moral objection to supplying a lawful product should ensure the patient is referred promptly to another pharmacist or pharmacy so lawful care is not obstructed — objection protects the practitioner's conscience, it does not license obstruction or judgement of the patient.

Fitness to practise is a collective duty. A colleague practising while impaired — through substance misuse, untreated illness or conduct that endangers patients — should be supported toward help, but where patient safety is at risk there is a duty to report to the employer and, where necessary, the licensing authority. Protecting patients outranks protecting a colleague's reputation.

Generic Substitution

Generic substitution means dispensing a different manufacturer's product containing the same active ingredient, strength and dosage form in place of the prescribed brand. Its legal and scientific basis is bioequivalence: a registered generic must demonstrate that its rate and extent of absorption fall within the accepted equivalence limits of the reference product (conventionally, the 90% confidence interval for key pharmacokinetic measures lies within 80–125%). Because registered generics meet this standard, substitution is permitted — and often encouraged by payers — unless an exception applies:

• The prescriber has explicitly marked no substitution or brand-necessary dispensing.
• The medicine is a narrow-therapeutic-index (NTI) or critical-dose drug where small exposure shifts matter — classic examples are levothyroxine, phenytoin, warfarin and ciclosporin. Many authorities and guidelines advise keeping patients on a consistent product for these, and any enforced switch warrants monitoring.
• No registered, bioequivalent generic exists for that product in the UAE market.

When a switch is made, the pharmacist should inform the patient, explain that appearance may differ while the active ingredient is unchanged, record the product dispensed, and counsel the patient to report any change in effect or new adverse effects — this documentation protects continuity if a problem later surfaces.

Generic vs therapeutic substitution

Confusing these two is a classic exam trap: swapping omeprazole for esomeprazole, or one ACE inhibitor for another, is therapeutic substitution and needs the prescriber's authorisation, however reasonable it seems clinically.